Skip to content
Search
Please enter at least 3 characters.

Latest Stories

'Wegovy could be key to curing heart failure'

Novo Nordisk said its hugely popular drug Wegovy was shown to substantially ease heart failure in obese people, as the Danish drugmaker seeks to further build its case for the medicine's health benefits beyond weight loss.

In a statement on Friday, the company said that after one year on Wegovy participants in the late-stage study lost weight and had a 16.6-point improvement on a 100-point health scale based on a range of heart failure-related criteria.


People in a parallel group without the treatment in the trial, known as STEP HFpEF, saw a 8.7 point improvement, resulting in an estimated net benefit from Wegovy of 7.8 points.

The trial with 529 volunteers focused on a heart condition known as 'preserved ejection fraction', or HFpEF, where heart muscles stiffen and draw in less blood, mainly affecting overweight people.

The drug was shown to be "able to ease the disease burden for people with HFpEF and obesity in a substantial way,” said Martin Lange, head of development at Novo.

Novo this month raised the prospect of additional health benefits from taking Wegovy, apart from losing weight and cutting the risk of heart disease, as shown in a larger separate trial known as SELECT.

The Danish drugmaker also earlier this month published better-than-expected headline results from that study, saying the weekly injection cut the risk of heart attacks and strokes by 20 per cent.

HFpEF accounts for about half of heart failure cases, with symptoms including shortness of breath and swelling of extremities.

The company said in a presentation in June that the drug had "demonstrated superiority" in that trial.

It said on Friday it would discuss the trial with regulators, who could potentially approve a wider use.

Showing specific medical benefits is crucial for Novo's push to move Wegovy beyond its image as a lifestyle drug.

Novo's latest research was also presented on Friday (August 25) at the European Society of Cardiology (ESC) Congress in Amsterdam and published in the New England Journal of Medicine.

More For You

Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
RPS transition to Royal College

RPS transition to Royal College: What it means for pharmacy

RPS transition to Royal College: What it means for pharmacy - Professor Claire Anderson explains

The Royal Pharmaceutical Society (RPS) is set to transition into a Royal College after securing majority support from its members in a recent ballot. However, concerns have been raised about the long-term implications of this shift.

With a voter turnout of 31.4%, 6,144 out of 19,594 eligible members participated in the vote on the Royal Charter changes. Of those, 71.1% supported the transition, well above the required two-thirds majority for a Special Resolution Vote.

Keep ReadingShow less
Pharmacies key to driving the shift from treatment to prevention

Bas Vorsteveld, Kenvue’s area managing director for Northern Europe.

Pharmacies can become frontline educators of self-care

Pharmacies have the potential to play a pivotal role in the government's transition from treatment-based healthcare to a more prevention-focused approach. However, for this shift to be successful, they require greater systemic support.

Bas Vorsteveld, Kenvue’s area managing director for Northern Europe, emphasises the importance of allowing pharmacists access to patient records to enable them to offer tailored advice and improve patient care.

Keep ReadingShow less
Community pharmacist consulting with a patient about independent prescribing.

Malcolm Harrison

Exclusive: National prescribing service 'critical' for community pharmacy, says Malcolm Harrison

A national prescribing service is “critical” for community pharmacy with all newly qualified pharmacists becoming independent prescribers from next year, according to Malcolm Harrison, chief executive of the Company Chemist Association (CCA).

“We are encouraging the NHS to work with community pharmacy to explore what that (prescribing service) could look like. There are pilots that are out there at the moment, and I know a number of pharmacies are engaged in those and exploring the different variations of what it could be,” Harrison told Pharmacy Business.

Keep ReadingShow less
Unlocking the potential of technology in pharmacy

Harry McQuillan, chairman, Numark

Technology in pharmacy goes beyond operational improvements

Community pharmacies are expected to take on greater responsibilities to ease pressure on other healthcare services and meet growing patient demands. However, despite their expanding role, they continue to lack adequate financial support.

“While funding negotiations continue, one thing remains clear, technology is key to ensuring pharmacy can thrive in a rapidly evolving healthcare landscape,” said Harry McQuillan, chairman of Numark.

Keep ReadingShow less